Nuveen LLC Makes New $44.08 Million Investment in QIAGEN N.V. $QGEN

Key Points

• Nuveen LLC has invested approximately $44.08 million in Qiagen N.V., acquiring over 1.1 million shares, representing 0.50% ownership of the company.
• Qiagen reported earnings of $0.60 per share for the last quarter, meeting expectations, while revenue increased by 7.7% year over year to $533.54 million.
• The company recently declared a $0.25 dividend, with a current dividend yield of 52.0%, indicating a relatively low payout ratio of 14.79%.

Nuveen LLC bought a new stake in shares of QIAGEN N.V. (NYSE:QGEN - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund bought 1,102,961 shares of the company's stock, valued at approximately $44,078,000. Nuveen LLC owned approximately 0.50% of QIAGEN at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Exchange Traded Concepts LLC lifted its holdings in shares of QIAGEN by 2.3% during the first quarter. Exchange Traded Concepts LLC now owns 17,825 shares of the company's stock worth $716,000 after buying an additional 395 shares during the last quarter. LPL Financial LLC lifted its holdings in shares of QIAGEN by 2.6% during the fourth quarter. LPL Financial LLC now owns 17,240 shares of the company's stock worth $768,000 after buying an additional 432 shares during the last quarter. Commerce Bank lifted its holdings in shares of QIAGEN by 20.4% during the fourth quarter. Commerce Bank now owns 5,931 shares of the company's stock worth $264,000 after buying an additional 1,004 shares during the last quarter. Cetera Investment Advisers lifted its holdings in shares of QIAGEN by 14.4% during the fourth quarter. Cetera Investment Advisers now owns 11,297 shares of the company's stock worth $505,000 after buying an additional 1,418 shares during the last quarter. Finally, GAMMA Investing LLC lifted its holdings in shares of QIAGEN by 93.9% during the first quarter. GAMMA Investing LLC now owns 2,943 shares of the company's stock worth $118,000 after buying an additional 1,425 shares during the last quarter. Hedge funds and other institutional investors own 70.00% of the company's stock.

Analyst Ratings Changes

A number of brokerages have recently commented on QGEN. Bank of America upped their price target on QIAGEN from $50.00 to $53.00 and gave the stock a "buy" rating in a report on Thursday, June 26th. Barclays assumed coverage on QIAGEN in a research note on Tuesday, June 24th. They issued an "overweight" rating and a $55.00 target price for the company. UBS Group upped their target price on QIAGEN from $48.00 to $50.00 and gave the company a "neutral" rating in a research note on Thursday, August 7th. Cowen restated a "hold" rating on shares of QIAGEN in a research note on Thursday, August 7th. Finally, Wall Street Zen lowered QIAGEN from a "strong-buy" rating to a "buy" rating in a research note on Monday, August 11th. Three investment analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $49.69.

QIAGEN Price Performance

NYSE:QGEN traded down $0.0660 during trading hours on Thursday, reaching $49.1340. The company had a trading volume of 695,538 shares, compared to its average volume of 1,386,155. The stock has a 50-day moving average of $48.56 and a two-hundred day moving average of $43.85. QIAGEN N.V. has a one year low of $37.63 and a one year high of $51.88. The firm has a market capitalization of $10.92 billion, a PE ratio of 29.03, a PEG ratio of 2.58 and a beta of 0.64. The company has a quick ratio of 1.35, a current ratio of 1.61 and a debt-to-equity ratio of 0.25.

QIAGEN (NYSE:QGEN - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The company reported $0.60 earnings per share for the quarter, meeting analysts' consensus estimates of $0.60. The firm had revenue of $533.54 million for the quarter, compared to analysts' expectations of $523.97 million. QIAGEN had a return on equity of 14.77% and a net margin of 18.30%.The business's revenue was up 7.7% compared to the same quarter last year. During the same period in the prior year, the business posted $0.55 earnings per share. QIAGEN has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. Analysts forecast that QIAGEN N.V. will post 2.26 earnings per share for the current year.

QIAGEN Announces Dividend

The company also recently declared a dividend, which was paid on Thursday, July 10th. Investors of record on Thursday, July 3rd were issued a $0.25 dividend. The ex-dividend date was Wednesday, July 2nd. This represents a yield of 52.0%. QIAGEN's dividend payout ratio (DPR) is currently 14.79%.

About QIAGEN

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.